1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
695A1039133C9BBB1852574430070C49E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-bio-pharma-merger-and-acquisition-integration-benchmarks?opendocument
18
19opendocument
203.87.147.184
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Mergers and Acquisitions

Bio-Pharma Merger & Acquisition Integration: Benchmarks for Success

ID: 4997


Features:

14 Data Graphics

221 Metrics

29 Best Practices


Pages/Slides: 108


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
With many factors influencing the outcome of the bio-pharmaceutical merger & acquisition process, achieving bio-pharmaceutical merger & acquisition integration success has become increasingly difficult. In this benchmarking study, bio-pharma integration leaders and senior staff from 26 pharmaceutical and biotechnology companies share their strategies, proven practices and key pitfalls when combining bio-pharma technology, product lines and companies.


Key topics covered are: successful M&A integration planning; structure, processes & best practices that lead to M&A integration excellence; risk factors to assess and manage in the integration process; measurement of M&A integration success & its representation; critical success factors and pitfalls in the integration process. This study would help executives involved in the bio-pharma merger & acquisition process to improve the effectiveness of their integration initiatives.


Industries Profiled:
Medical Device; Pharmaceutical; Biotech; Health Care; Manufacturing


Companies Profiled:
3M Pharmaceuticals; Takeda Pharmaceuticals; Solvay Pharmaceuticals; SIRO Clinpharm; QLT Inc.; Pfizer; Nizhpharm; Merial; Medtrina; Lilly; Kimble Chase; Johnson & Johnson Healthcare Systems; Indoco; Incite World; Heel; Eisai; Covidien; Coloplast; Baxter Healthcare; ATG; Alexza Pharmaceuticals; Allergan; Absolute Science; Abbott Laboratories


Study Snapshot

The data for this benchmarking study was collected utilizing an online survey instrument and several deep-dive executive interviews. Bio-pharma integration leaders and senior staff from 26 pharmaceutical and biotechnology companies participated in this research.

Key topics include:
  • Structure for Integration
  • Pre-Integration Planning Activities
  • Integration Risk Management
  • Integration Functional Excellence
  • Communications Excellence
  • Understanding & Managing Cultural Issues
  • Post-Deal Closure Integration Activities
  • Trends in M&A Integration
  • Integration Lessons Learned

Sample Key Findings

Integration structure should reflect the acquired assets & business objectives
  • Communications excellence is a foundation for succesful integration
  • Understanding and managing cultural issues is vital to assessing and executing successful integration

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.